ABOUT US
Huabo Biopharm Co., Ltd., (aka ‘Huabo Biopharm’), established in June 2011, is a subsidiary of Shanghai Huaota Pharmaceutical Co., Ltd. At Huabo Biopharm, the R&D team is led by two distinguished experts. As one of the inventors of a blockbuster biologics, Skyrizi, Dr. Xiangyang Zhu has more than 20 years of industry experience in novel biological drugs development. Dr. Yifan Zhan is a senior scientist with more than 30 years research experience in the field of immunology. The team has rich experience in the development of biotherapeutics including monoclonal antibodies, bispecific antibodies, and fusion proteins. Huabo Biopharm was certified as High- and New-Technology Enterprise in 2018 and has undertaken and completed many science and technology projects in collaboration with universities, research institutes, and other research organizations in China and globally. Huaobo Biopharm has applied for over 20 domestic and international invention patents.
Huabo Biopharm focuses on the research and development of new biological drugs in different therapeutic areas including tumors and autoimmune diseases. Comprehensive R&D platforms have been well established for antibody discovery, cell line development, upstream and downstream process development, protein quality research and structural characterization, antibody function analysis, and formulation development. Currently, there are almost twenty research projects under development, many of them have obtained IND approval for clinical trials. The flagship Project HB0025 has entered phase I trial in both the United States and China as the world’s first bispecific antibody against PD-L1 and VEGF fusion protein for the treatment of solid tumors.
Merging of Zhejiang Huahai Biopharmaceuticals Co., Ltd. as a subsidiary of Huaota focusing on manufacturing of phase III clinical trial supplies and commercial products
Multiple projects obtained IND approval (HB0025 from FDA, HB0030 from CDE, HB0034 from New Zealand)
In January, Huaota received Manufacture License of Pharmaceutical Products
Multiple projects obtained IND approval （HB0017 ，HOT-1030，HB0025， HB002.1M）
In June, Huaota entered into an agreement with Shanghai Junshi Biosciences Co., Ltd; Junshi acquired the Avastin monoclonal antibody biosimilar (project code "HOT-1010") from Huaota
In December, Huaota was certified as High –and New-Technology Enterprise
In November, Huabo Biopharm was certified as High –and New-Technology Enterprise
In March, Huaota completed the shareholding system reform and renamed “Shanghai Huaota Biopharmaceutical Co., Ltd.”
In March, Huaota started the first clinical trial: Phase I study of HB002.1M, a VEGFFR1-Fc for ophthalmic injection
In September, Huahai Pharmaceutical reached a strategic collaboration with Korea Eutilex Co., Ltd.
In June, Huaota received the first IND approval for clinical trial of the project HB002.1M, a VEGFFR1-Fc for ophthalmic injection
In August, Huaota’s pilot plant was officially launched.
In September, Huaota was established
In May，Huahai Pharmaceutical reached a strategic collaboration with US Oncobiologics Inc.
In June, Huabo Biopharm was established
Innovation brings the future， Quality makes the brand
To establish a world class biopharma developing high-quality yet affordable novel biologics to address unmet medical needs globally
Innovation, Quality, Perseverance
Open-mindedness, Collaboration, Integrity, Dedication
